⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 1, 2010British Journal of PharmacologyOpen Access

Value of non‐clinical cardiac repolarization assays in supporting the discovery and development of safer medicines

View Full Paper

Ask AI

Bookmark

Share

Design

Review

Authors

JVJean‐Pierre ValentinUCB Pharma (Belgium)CPChris PollardSouth Yorkshire Fire and Rescue PLPierre LainéeSanofi (France)

Discussion

Loading...

Member takes

Implication

Non-clinical QT assays aid regulatory drug approval; this review extends their role but leaves optimal integration open for further study.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Valentin et al. (2010) studied this question.

synapsesocial.com/papers/6a83e6fc5dc7077fe9c58e73 https://doi.org/10.1111/j.1476-5381.2009.00530.x

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety pharmacology – a progressive approach2002 · 100 citations
2Drug‐induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives2009 · 112 citations
3Dog left ventricular midmyocardial myocytes for assessment of drug‐induced delayed repolarization: short‐term variability and proarrhythmic potential2009 · 45 citations
4Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study2007 · 127 citations
5Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death2005 · 245 citations